Coverage & Funding Pathways

These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.

A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.

Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.

The 2022 National Medical Security Industry Development Statistical Bulletin, along with the Basic Medical Insurance operation data for Q1 to

Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access Pathways

Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai

Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.

Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect